Dexmedetomidine
Selective alpha-2 adrenergic agonist sedative that produces calm, rousable sedation resembling natural sleep.
Pharmacology
Contents
WHAT IS DEXMEDETOMIDINE?
Detailed overview
Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist used mainly for sedation in the intensive care unit and for short surgical or diagnostic procedures. By inhibiting noradrenaline release in the locus coeruleus, it engages the ventrolateral preoptic nucleus to produce an easily rousable sedation that resembles natural non-REM (especially deep, N3) sleep, with minimal respiratory depression. It is FDA- and EMA-approved and used only under medical supervision in injectable or sublingual (Igalmi film) form. It is not an over-the-counter supplement: it is listed here for reference and education, to illustrate sleep neuropharmacology.
Mechanism
Selective alpha-2A agonist (locus coeruleus)
Half-life
About 2-3 hours
Legal status
Prescription medicine (FDA/EMA)
Receptor profile
- Alpha-2 adrenergic receptors (mainly alpha-2A)Strong
- Locus coeruleus noradrenaline releaseStrong
- Ventrolateral preoptic nucleus / GABA signalingModerate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Bradycardia (slow heart rate), sometimes pronounced
- Hypotension (low blood pressure) from reduced sympathetic tone
- Transient blood pressure spike during a rapid loading dose (bolus) from peripheral vasoconstriction
- Dry mouth
- Excessive or prolonged sedation, especially with hepatic or renal impairment
- Withdrawal symptoms on abrupt discontinuation after prolonged infusion: rebound hypertension, tachycardia, agitation
Contraindications · 5
- Only for use under medical supervision in a monitored setting (intensive care, anaesthesia)
- Advanced heart block (2nd or 3rd degree AV block) without a pacemaker, severe bradycardia
- Uncontrolled hypotension, uncompensated circulatory failure
- Pregnancy and breastfeeding: safety not well established, only if clearly beneficial
- Severe hepatic impairment: requires dose reduction due to slower clearance
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial
Skrobik Y, Duprey MS, Hill NS, Devlin JW
Early Sedation with Dexmedetomidine in Critically Ill Patients
Shehabi Y, Howe BD, Bellomo R, et al.
Effect of mini-dose dexmedetomidine supplemented intravenous analgesia on sleep structure in older patients after major noncardiac surgery: A randomized trial
Song B, Li Y, Teng X, et al.
Effects of pharmacological therapy on sleep quality in a postoperative setting: A systematic review of randomized controlled trials
Systematic review
Dexmedetomidine Sedation in Mechanically Ventilated Critically Ill Children: A Pilot Randomized Controlled Trial
Kalyanaraman M, et al.
FAQ
FAQ
Selective alpha-2 adrenergic agonist sedative that produces calm, rousable sedation resembling natural sleep.
Telegram
Have a question about Dexmedetomidine?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.